Supplementary Tables – Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece

Supplementary Table 1: Fist-line Therapy Characteristics, Discontinuation and Switch to 2L. Supplementary Table 2: T790M mutation testing among patients progressing on or discontinued from 1L EGFR-TKI and Treatment Options. Supplementary Table 3: Third-, Fourth- and Fifth-line treatments.